Chronic Hepatitis B Virus Infection and Pregnancy

Manoj Kumar**, Tarandeep Singh**, Swati Sinha*

"Department of Obstetrics and Gynecology, Siritar Bhatra Institute of Science and Research, B-16, Qutub Institutional Area, New Delhi 110016, **Department of Hepatology, Institute of Liver and Biliary Sciences, D-1, Vasant Kunj, New Delhi 110070, India

Planning of pregnancy and management of chronic hepatitis B virus during pregnancy includes recognition of maternal virological status, assessment of liver disease severity and minimization of risk for mother to infant transmission of infection. Decisions regarding the use of antivirals during pregnancy need to be individualized. Monitoring for infection and immunization in newborns is also important. For mothers on antiviral therapy, breastfeeding is not recommended. (J CLIN EXP HEPATOL 2012;2:366–381)

A pproximately 400 million people are chronically infected with hepatitis B virus (HBV) worldwide,1 and almost half have acquired their infections either through mother to infant transmission or in early childhood, especially in countries where HBV has intermediate to high prevalence.2 In Asia, 8%–10% of the population is chronically infected with HBV, and up to 50% of new cases of hepatitis B infection are due to mother to infant transmission.3 In contrast, the majority of new hepatitis B cases in developed countries are the result of horizontal transmission in adulthood. Before the adoption of standard passive–active immunoprophylaxis treatment, approximately 70%–90% of infants born to hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers became chronically infected with HBV.4 The mother to infant transmission rate was reduced to 5%–10% when infants received appropriate postnatal hepatitis B immunoglobulin (HBIG) and a series of HBV vaccines. However, despite passive–active immunoprophylaxis provided to infants, up to 8%–30% of infants born to highly viremic mothers still become infected with HBV (Figures 1–3).

This review will address several issues important to chronic hepatitis B virus infection and pregnancy includ-

Keywords: pregnancy, chronic hepatitis B, breast feeding

Received: 14.7.2012; Accepted: 6.9.2012; Available online: 20.9.2012

Address for correspondence: Manoj Kumar, Department of Hepatology, Institute of Liver and Biliary Sciences, D-1, Vasant Kunj, New Delhi 110070, India.

E-mail: manojkumardm@gmail.com

Abbreviations: HBV: hepatitis B virus; HBsAg: hepatitis B surface antigen; HBeAg: hepatitis B e antigen; HBcAg: hepatitis B core antigen; ALT: alanine aminotransferase; APRT: Antiretroviral Pregnancy Registry; DART: Development of Antiretroviral Therapy Study; HIV: human immunodeficiency virus; CDC: Centers for Disease Control and Prevention; PHACS: Pediatric HIV/AIDS Cohort Study; RCTs: randomized clinical trials; FDA: Food and Drug Administration; ECS: elective caesarian section; CI: confidence interval; EASL: European Association for the Study of the Liver; NA: nucleos(t)ide analog; PEG-IFN: pegylated interferon; APASL: Asian Pacific Association for the Study of the Liver

http://dx.doi.org/10.1016/j.jceh.2012.09.001

The prevalence of chronic HBV infection varies widely, with rates ranging from 0.1% to 20% in different parts of the world.6 “High” prevalence (HBsAg positivity rates > 8%) regions include the Asia (except Japan), parts of the Middle East, sub-Saharan Africa, and the Amazon basin. “Intermediate” (2%–7% HBsAg positive) prevalence regions include, the Indian subcontinent, parts of central Asia and the Middle East, Eastern and Southern Europe, as well as parts of South America. “Low” prevalence (<2% HBsAg positive) regions include the United States, Northern Europe, Australia, Japan and the southern part of South America. Overall, 45% of the world population lives in “high” prevalence regions.

The HBsAg positivity rate of Hepatitis B in India is different in the different regions of the country. The overall chronic HBsAg positivity rate is often quoted as being 4.7%.5 In India, the prevalence rate of HBsAg positivity in pregnant women in studies before 1990s varies from 2.6 to 9.5%,5,14 whereas more recent studies have reported HBsAg positivity among pregnant women ranging from 0.8 to 1.1%.12,13 The HBeAg positivity among HBsAg positive pregnant women have varied widely from 4.8% to 68.7%.6,14 In a recent study from Delhi, which found HBsAg prevalence of 1.1% among pregnant women, it was found that the alanine aminotransferase (ALT) levels were normal in 54% of the women and HBV DNA levels were above 10,000 copies/mL (2000 IU/ml) in 71% of women. The median HBV DNA levels were higher in women who were HBeAg positive compared to the
HBeAg-negative group. The most common HBV genotype was D (84%) followed by A + D and A (8% each).14

EFFECT OF PREGNANCY ON CHRONIC HEPATITIS B VIRUS INFECTION

No worsening of liver disease occurs in the majority of women during pregnancy and liver enzymes frequently normalize. However, case reports of hepatic exacerbations/fulminant hepatic failures in HBsAg-positive pregnant women have been reported.15,16

A proportion of women have hepatitis flares with or without HBeAg seroconversion (12.5–17%) within the first months after delivery.17–19 Among HBeAg positive chronic HBV-infected mothers, low HBeAg titers and low HBV DNA viral loads have been associated with HBeAg loss after delivery.19 In a recent study from Netherlands, among pregnant patients with chronic HBV infection, there was an overall increase in median HBV DNA levels during pregnancy, which declined after pregnancy. Median ALT values also decreased during pregnancy and a significant increase in liver disease activity after pregnancy, defined as a three times increase in alanine aminotransferase (ALT) within 6 months after delivery, occurred in 45% of patients.17 It is important to appreciate the variability in the clinical manifestation of acute flares of chronic hepatitis B during the peri-partum period. It may range from mild flare to severe flares and even leading to death or requiring liver transplant.20,21

HBV is a noncytopathic virus and the associated hepatic inflammation is mainly mediated by the host’s immune

Figure 1 Suggested management of chronic HBV infection in women who desire pregnancy.

Figure 2 Suggested management of chronic HBV infection in women who become pregnant while taking antivirals.
response. In patients with chronic HBV infection an inadequate immune response of the host plays an important role in the development of chronicity.\(^{22}\) During pregnancy, there are numerous alterations in the maternal immune system to prevent rejection of the fetus.\(^{23}\) Several factors are produced by both the fetal trophoblast and the maternal uterine tissue like CD95L (Fas ligand), indoleamine 2, 3-dioxygenase and leukemia inhibitory factor; also there is a shift in the T helper cells (TH1–TH2) balance toward a TH2 response with increased amounts of regulatory T cells (contributing to an inadequate immune response against the virus).\(^{24}\) All these changes in the immune status recover after delivery and the immune system fully restores its function. The reactivation of the immune system is responsible for the high amount of patients with a post pregnancy increase in ALT.\(^{17}\) It is thus prudent to monitor HBV-infected women closely for several months after delivery for hepatitis flares and seroconversion.

**EFFECT OF CHRONIC HEPATITIS B VIRUS INFECTION ON PREGNANCY**

Many reports are available with varied results on the effects of chronic HBV infection on the outcome of pregnancy. Although few reports found no association of HBV infection with adverse pregnancy outcomes in chronically HBV-infected mothers, a few studies from Hong Kong and Israel have found that chronic HBV-infected mothers have increased risk for threatened preterm labor and preterm delivery.\(^{25,26}\) However, these studies did not assess maternal HBeAg status or serum or cord blood HBV DNA levels during pregnancy. One recent study from Greece, showed a significant association between spontaneous preterm birth and presence of HBV DNA in the cord blood. HBV DNA positivity in cord blood was significantly associated with maternal HBV DNA levels.\(^{27}\) Many studies have suggested the use of nucleos(t)ide analog therapy with an appropriate anti-HBV agent for managing HBV infection in mothers whose serum tests positive for HBsAg and who have high serum HBV DNA concentrations in last trimester.\(^{28}\) Whether the use of antiviral agents in chronic HBV-infected mothers with high serum HBV DNA concentrations throughout or during the last trimester of pregnancy, could result in lower obstetric complications including preterm birth is an interesting area.\(^{29}\)

**MOTHER TO INFANT TRANSMISSION**

**Definitions**

Mother to infant transmission (also known as vertical transmission or perinatal transmission) is the transmission of an infection or other disease from mother to child immediately before and after birth. Transmission might occur either while the baby is still in the uterus (prenatal, antepartum, in utero or intrauterine transmission), during the delivery process (natal or intrapartum transmission), or shortly after birth (postpartum or during child care or through breast milk) [see below]. Although the transmission of infections from mother to infant is popularly known as perinatal infection; it is not synonymous to infections during the perinatal or neonatal period. Perinatal period is an interval extending approximately from the 28th week of gestation to the 28th day after birth. Therefore, by definition, in utero infections in the first or second trimester of pregnancy are not considered as perinatal infection. Therefore, the term perinatal transmission may
be avoided and instead use the term mother to infant transmission or vertical transmission.24

For a newborn infant whose mother is positive for both HBsAg and HBeAg, the risk for chronic HBV infection is 70%-90% by age 6 months in the absence of post exposure immunoprophylaxis. For infants of women who are HBsAg positive but HBeAg negative, the risk for chronic infection is <10%-40% in the absence of post exposure immunoprophylaxis. 85-95% of infected infants will become chronic HBV carriers. Rare cases of fulminant hepatitis B among perinatally infected infants also have been reported. Mother to infant transmission, mainly from HBeAg negative, HBsAg positive mothers, is the most important route of transmission for acute or fulminant hepatitis in infancy.24,30 The incidence of fulminant hepatitis B is higher in infancy than in other age periods.30

Risk Factors for Mother to Infant Transmission

HBeAg may be filtered through the placenta.31 Although, maternal HBeAg positivity has been suggested as an independent risk factor for mother to infant transmission,32 this finding has not been confirmed by other studies.33,34 In a study from China, in 54 mother–infant pairs (33 mothers were HBeAg positive, and 21 HBeAg negative; all babies received passive–active immunoprophylaxis with hepatitis B immune globulin and hepatitis B vaccine), 70% (23/33) of neonates from HBeAg-positive mothers were HBeAg positive at birth compared with 0% (0/21) of neonates from HBeAg-negative mothers. HBeAg was present at higher titer in the birth sera of the babies with HBV breakthrough than in babies without breakthrough. HBeAg was cleared from the serum in all 19 babies without breakthrough. In 17 of these 19 babies, the HBeAg was cleared within 6 months, and in two babies clearance took 12 months. The mean serum HBV DNA level in the mothers of the infants with HBV breakthrough was significantly higher than in the mothers of babies who did not become infected.35 Thus, he study concluded that HBeAg can cross the human placenta, and disappears from serum within 6 months in most babies. HBV DNA levels in hepatitis B infected mothers are associated with the failure of HBlg and vaccine immunization [see below], and the additional influence of transmitted HBeAg cannot be excluded.

Among HBeAg-positive mothers, lower Hepatitis B core (anti-HBc) titers were associated with a higher incidence of mother to infant transmission. A high maternal anti-HBc level in serum may be a negative predictor of immunoprophylaxis failure in high-risk infants.36

Hepatitis B Virus Deoxyribonucleic Acid

Serum HBV DNA level has been identified as the single most important predictor and independent risk factor for mother to infant transmission. Earlier studies found that prophylaxis effective rate of passive–active immunoprophylaxis is approximately 100% if maternal prelabor HBV DNA levels were <5.5 log10 copies/mL, as compared with 2/3rd of cases if maternal DNA levels were more than these levels.37,38 One Canadian study found that the maternal HBV DNA level of >8 log10 IU/mL was associated with increased likelihood of immunoprophylaxis failure.39 Another study from Australia found that the risk of mother to infant transmission increased with maternal HBV DNA levels >8 log10 copies/mL and no transmission was seen in babies of mothers with HBV DNA levels <8 log10 copies/mL.35 However, till recently it was not clear whether lower levels of maternal HBV DNA may have a significant impact on immunoprophylaxis failure. A recent large study on more than a thousand mother–infant pairs from China demonstrated that immunoprophylaxis failure only occurred in infants born to HBeAg-positive mothers. When maternal predelivery HBV DNA levels were stratified to <6 log10 copies/mL, 6-6.99 log10 copies/mL, 7-7.99 log10 copies/mL, and ≥8 log10 copies/mL, the corresponding rates of immunoprophylaxis failure were 0%, 3.2%, 6.7%, and 7.6%, respectively (P < 0.001).34 One Indian study found that HBV transmission (detection of any of the HBsAg, HBeAg, or HBV DNA in cord blood or peripheral blood of neonates) occurred in 78% of cases with maternal HBV DNA levels ≥1.5 × 10⁵ copies/mL as compared with 47% in cases with maternal HBV DNA levels <1.5 × 10⁵ copies/mL.40 Thus, the maternal HBV DNA level of >6 log10 copies/mL at delivery seems to be the most important predictor for MTCT. There is a nonlinear correlation between infant and maternal HBV DNA levels in the prophylaxis failed group indicating that increased maternal–fetal gradient across the placenta is not playing a part in transmission.41 There is a suggestion that high levels of maternal HBV DNA may enhance HBV transmission to embryos.42

HBV Genotypic Variations

Eight genotypes of HBV have been defined (forms A–H). Different genotypes are distributed in different geographical areas. For example, genotypes B and C are prevalent in Asia, while genotypes A and D are more common in Europe, the Middle East and India. The prevalence among pregnant women reflects their distribution in general population in that particular region. Genotype can be a factor associated with viral load and frequency of vertical transmission. For example, despite similar high prevalence of HBV chronic carriers, the rate of maternofetal infection in east Asia, particularly China, was estimated to range between 10 and 88%,43,44 compared with 8% or less in studies conducted in sub-Saharan Africa.45,46 This difference can be largely attributed to the natural history of HBV infection of genotype B and C, as in south-east Asia where infected individuals carry HBeAg and high viral load in age
groups that include most women of gestational age.\textsuperscript{46,47} In contrast, in sub-Saharan Africa, whether infected with HBV genotype A1 or E, seroconversion to anti-HBe occurs before age 15 or 16, with the consequence that most women of gestational age carry anti-HBe.\textsuperscript{48} In a study, there was no particular HBV genotype (genotypes B and C were included in the study) significantly associated with the loss of HBeAg among the mothers after delivery.\textsuperscript{19} In a study from Japan, the relationship between routes of HBV transmission and HBV genotypes was studied in 118 children (98% had chronic HBV infection, and 2% had acute hepatitis). Genotype C (86%) was the most frequent, followed by genotype B (9%), D (2.5%), and A (1.0%). Transmission routes of HBV to children were from mothers in 91 patients (77%), fathers in 8 (6.5%), mother or father in 1 (1%), family members other than the parents in 5 (4%), and unknown in 13 (11.5%). Eighty-eight (97%) of 91 children of mother to infant transmission were genotype C, while 13 (49%) of 27 children of the routes other than the mother to infant transmission were genotype C. The number of children with genotype C who were infected from their mothers was significantly higher than those with genotype B, D, or A ($P < 0.01$).\textsuperscript{49} However, other studies have not found any association between HBV genotype and vaccination failure.\textsuperscript{50,39} However, due to specific distribution of genotypes in particular areas, and lack of studies on comparative role of different HBV genotypes in transmission of hepatitis B virus to offspring, further studies are warranted to define the role of HBV genotypes in mother to infant transmission.

The role of mutants in S gene (which might occur naturally or after vaccination) in vaccine failure remains inconclusive. Recent studies showed no difference between success and failure groups to immunoprophylaxis in terms of mutation rate, but the mutation distributions differ. In a study from China, 41 mothers from whom HBV transmission to their children was prevented were compared with 37 mothers whose children were HBsAg positive 1 year after HBV vaccination. Although the DNA loads in mothers of the failure group were significantly higher than those in the success group; no difference was found in the S gene mutation rate and genotypes between the groups. Interestingly, Thr123Ala and Gly145Arg were observed only in failure-group mothers, whereas Thr126Asn, Thr126Ser, Thr143Asn, Asp144Gly, and Asp144Ala were seen in the success group. Thus, high viral load is an important risk factor for HBV vaccination failure, which is correlated with the positions of mutations in the S gene, but not with mutant frequencies or genotypes.\textsuperscript{50} HBIG does not play a role in the development of S mutants.\textsuperscript{39} The role of precore and basal core mutations in mother to infant transmission has not yet been fully explored, although infants born to mothers with HBV precore mutations may be more likely to have HBeAg-negative fulminant hepatitis if mother to infant transmission occurred.\textsuperscript{51}

**Occult Hepatitis B Virus Infection**

Occult HBV infection is the long-lasting persistence of viral genomes in the liver tissue (and in some cases also in the serum) of individuals negative for the HBsAg by currently available assays.\textsuperscript{52,53} In woodchucks, mothers with occult woodchuck hepatitis virus transmitted virus to their offspring.\textsuperscript{54} Vertical transmission of occult HBV from pregnant woman to the fetus has also been described.\textsuperscript{55} One Korean study on 202 healthy pregnant women, where HBV DNA testing was performed using two specific quantitative tests with two independent sets of sera and cord blood, found that 8 of 202 (4%) individuals with the TaqMan PCR assay and 23 of 202 (11.4%) with the COBAS Amplicor HBV Monitor test were HBV DNA positive. Six (3%) individuals were positive with both methods. Cord blood obtained from four of six individuals who were positive with both the HBV DNA methods, was HBV DNA negative.\textsuperscript{56} Thus, the vertical transmission of occult HBV infection through cord blood although possible is not so high as to be a clinical problem, but warrants further investigation in population-based studies.

**Routes of Mother to Infant Transmission**

There are three possible routes of transmission of HBV from infected mothers to infants: prenatal (antepartum or in utero or intrauterine), natal transmission (intrapartum or during delivery) or postnatal (Postpartum or during child care or through breast milk) transmission.

**Prenatal (Antepartum or In Utero or Intrauterine) Transmission**

At present, the combined immunity of hepatitis B vaccine and high-titer hepatitis B immunoglobulin (HBIG) has already achieved relatively excellent efficacies in blocking the maternal-infant transmission of HBV. However, still among around 10% of the mothers with positive HBV serum marker, the immunological blockade failed in the born neonates who later became chronically infected with HBV. In clinical practice, the tests of HBsAg and HBV DNA in fetal cord blood or neonatal peripheral blood are often performed to diagnose intrauterine HBV infection.\textsuperscript{57} Neonatal peripheral blood is better than cord blood for diagnosis of intrauterine infection as the possibility of the cord blood being contaminated by the maternal blood always remains.\textsuperscript{29} Intrauterine transmission is defined as detectable HBV DNA in neonatal peripheral venous blood.\textsuperscript{58}

It is currently thought that the major cause of unsuccessful immunological blockade is the prenatal or intrauterine transmission of HBV. The mechanisms of such an infection include:

1) Placental infection and transplacental transmission of HBV
Intrauterine HBV infection is mainly transmitted through the placenta from the maternal blood to the fetus. Transfer of HBV from cell to cell in the placenta has been suggested by a decreasing titer of HBcAg and HBsAg from the maternal to fetal side. HBV can infect all kinds of cells in placenta, with HBV transmission occurring either by HBV-infected cells from maternal decidua to villous capillary endothelia or by HBV-infected trophoblastic cells directly to villous mesenchymal cells and villous capillary endothelial cells. High level of serum HBV DNA in pregnant women is one of the high-risk factors for occurrence of HBV intrauterine infection [see above].

2) Transplacental leakage of maternal blood

Threatened preterm labor or spontaneous abortion, with the possible mixing of maternal and fetal blood, appears to increase the risk of HBV transmission.

3) Amniocentesis

Every genetic amniocentesis theoretically inoculates the intrauterine cavity with maternal blood because the needle traverses the abdominal and uterine wall. In fact, visible intrauterine bleeding can be seen in up to 38% of genetic amniocentesis procedures that do not involve the placenta. However, amniocentesis has not been shown to significantly increase mother to infant transmission rates in published studies, that were mainly based on infants’ HBsAg status without HBV DNA testing.

4) Other mechanisms

HBV can circulate to the fetus via maternal peripheral blood mononuclear cells. Intrauterine transmission might also occur via oocytes or sperms in HBV-infected persons.

Recently, polymorphisms in some cytokine genes, such as those encoding for interferon-γ and tumor necrosis factor α, have been correlated with risk of intrauterine infection with HBV.

Natal (Intrapartum) Transmission

It is widely accepted that most mothers to infants transmission occurs at or near the time of birth (natal transmission), because neonatal vaccination prevents newborn infection in about 80–95% of cases. Theoretical risks for HBV transmission at delivery include maternal–fetal microtransfusion during delivery or swallowing of infective fluid. A linear association was observed between the duration of the first stage (stronger association if duration > 9 h) and the presence of HBV antigens in cord blood. Partial placental leakage occurring during labor, trauma from instrumentation, and threatened preterm labor can result in the mixing of fetal and maternal circulation (microtransfusion) and lead to an increase in the risk of HBV infection. HBsAg and HBV DNA has been detected in vaginal epithelial cells, cervicovaginal cells, amniotic fluid and vaginal fluid samples of HBsAg positive mothers during pregnancy, raising the possibility that direct contact with the infective fluid in the maternal genital tract might also be responsible for the transmission of HBV to infants.

Postnatal (Postpartum) Transmission

Breastfeeding has been a major concern in postpartum HBV transmission because HBsAg has been detected in breast milk in a large proportion of HBV-infected women. In addition, HBsAg can be transmitted to the infant via abrasions around the mother’s nipple, although mother to infant transmission via this route is difficult to prove, as person-to-person transmission of HBV usually takes prolonged periods of close contact. After the availability of immunization, there was concern about the risk that breastfeeding might confer. However, studies have documented no difference in rates of perinatal infection between breastfed and formula-fed vaccinated infants. Thus HBV infection is not considered a contraindication to breastfeeding of infants who receive the HBIG and HBV vaccine. Breastfeeding does not interfere with the immune response to the HBV vaccine.

SAFETY DATA ON HEPATITIS B VIRUS ANTIVIRALS DURING PREGNANCY

Safety data on HBV antivirals during pregnancy come from two major sources: the Antiretroviral Pregnancy Registry (APR), and the Development of Antiretroviral Therapy Study (DART). The APR is an international, voluntary, prospective exposure registration cohort study of women exposed to antiretroviral therapies, most of whom are HIV-1 monoinfected. As of January 2012, data from 16,732 pregnancies (including 203 HBV monoinfected) were available. No significant difference has been reported in the rate of adverse outcomes if the initial exposure of any HBV drug was in the first trimester (2.7%) compared to the second or third trimester (2.5%) of pregnancy; which compares favorably to the 2.72% reported by the CDC birth defect surveillance system. However, APR only provided short-term prospective observational data on birth defects, but potential other side effects of antiretroviral agents and side effects occurring later in life in the child, are not available in the APR. Child’s long-term safety from the usage of antiviral agents during pregnancy has not yet been established.

The DART study is a multicenter, randomized trial of antiretroviral therapy among adults with symptomatic HIV-1 infection or advanced disease/AIDS in Africa. The 3% rate of congenital anomalies reported in this study also compares favorably to the 2.72% reported by the CDC birth defect surveillance system.

Lamivudine

In pregnant women, lamivudine crosses the placenta readily by simple diffusion. In a study of 57 HIV-infected
pregnant women receiving lamivudine as part of antiretroviral therapy, maternal blood, cord blood and amniotic fluid samples correlated with fetal concentrations; and the median concentration in the amniotic fluid was 5 times higher than in maternal plasma. Animal teratogenicity studies have been performed in rats and rabbits with exposure up to 40 and 36 times higher than human doses, respectively, with no observed teratogenicity. There was, however, a reduction in litter size of rabbits observed at exposures less than that observed at human clinical dosage.

Lamivudine is a pregnancy category C medication for HBV (Table 1). Its safety profile has been documented in human immunodeficiency virus (HIV) or HBV co-infected pregnant mothers in the APR. The infant birth defect rates for lamivudine exposure at the first and second/third trimesters were 127/4088 [3.1% (95% CI: 2.6%–3.7%)] and 186/6635 [2.8% (95% CI: 2.4%–3.2%)] respectively, which did not differ from those born to mothers without exposure to antiviral therapy. This statistic compares favorably to the 2.72% rate reported by the Centers for Disease Control and Prevention (CDC) birth defect surveillance system. There have been concerns about long-term carcinogenicity in children exposed to lamivudine in utero or postpartum. A recently reported prospective cohort found cancer incidence in 8853 children (median age 5.4 years) exposed to ≥1 antiretroviral drug (5908 received Lamivudine) during pregnancy or postpartum. The incidence did not differ significantly from the general population, with 10 tumors detected. Prematurity and exposure to the combination of didanosine/lamivudine remained independently associated with cancer, but the authors advised that long-term surveillance is warranted.

Thus of all the antivirals active against HBV, lamivudine has the most safety data in pregnancy.

**Table 1** Pregnancy category of FDA-approved treatments for chronic HBV.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Pregnancy category</th>
</tr>
</thead>
<tbody>
<tr>
<td>IFN alpha</td>
<td>C</td>
</tr>
<tr>
<td>Peg-IFN alpha</td>
<td>C</td>
</tr>
<tr>
<td>Adefovir</td>
<td>C</td>
</tr>
<tr>
<td>Entecavir</td>
<td>C</td>
</tr>
<tr>
<td>Lamivudine</td>
<td>C</td>
</tr>
<tr>
<td>Telbivudine</td>
<td>B</td>
</tr>
<tr>
<td>Tenofovir</td>
<td>B</td>
</tr>
</tbody>
</table>

**Category A drugs**: controlled studies in women fail to demonstrate a risk to the fetus.

**Category B drugs**: no teratogenic/embryogenic risk in animal studies and no controlled human studies available or risk in animal studies, but controlled human studies refute these.

**Category C drugs**: teratogenic/embryocidal effects in animals, and no controlled studies in humans.

**Category D drugs**: positive evidence of human fetal risk, but benefits from use in pregnant women may be acceptable despite the risk.

**Category X drugs**: positive evidence of human fetal risk and the risk of the use in pregnant women clearly outweighs any possible benefit.

**Tenofovir**

Studies on placental transfer of tenofovir (usually in association with other antiretroviral drugs) performed in HIV-infected women have reported a median ratio of maternal to umbilical cord concentration of 1.00, thus exposing infants to relatively high levels in utero. Reproductive toxicity studies in rats and rabbits did not reveal harmful effects to fetus at concentrations of 4–13 and 66 times higher than human exposure levels, respectively. In studies on gravid rhesus monkeys administered tenofovir subcutaneously once daily from 20 to 150 days of gestation, there was normal fetal development, although overall body weights and crown-rump lengths were less than those for age matched controls, along with a small reduction in fetal bone porosity. Safety issues for tenofovir-exposed infants include concerns about congenital abnormalities, renal function, bone mineralization, and growth. These concerns first arose from studies showing that high doses of tenofovir given to pregnant rhesus macaques caused bone demineralization, impaired somatic growth, and low levels of insulin-like growth factor-1 in their infants. Renal tubular leak of phosphate resulted in bone demineralization and deformities in macaque infants given high dose tenofovir, although these effects were largely reversible once tenofovir was stopped. Despite increasing numbers of infants being exposed to tenofovir in utero and use of off-label tenofovir in HIV-infected children, data on its effects on renal function, bone mineralization, and growth remain relatively sparse; in particular, few studies have included a control group. A recent report from DART study found no evidence of increased renal impairment or hypophosphatemia among infants exposed in utero to tenofovir- versus non-tenofovir-containing Antiretroviral therapy (ART), whereas, other studies have found decreased bone mineral density and hypophosphatemia in children receiving tenofovir versus controls. Although abnormalities appear to normalize following withdrawal of tenofovir, more long-term data are needed in children receiving tenofovir from an early age. Longer term data on bone health in both tenofovir-exposed HIV-infected children and infants exposed to in utero tenofovir are needed. With respect to
growth among tenofovir-exposed infants, the US Pediatric HIV/AIDS Cohort Study (PHACS) of 532 infants reported lower weight but not height at 1 year among those exposed versus not exposed to tenofovir in utero, although the effect was unrelated to duration of tenofovir exposure and was not present at birth.66 The authors concluded that tenofovir should remain an “alternative” rather than “recommended” drug during pregnancy as per current US guidelines.87

Telbivudine
In preclinical animal studies, telbivudine crossed placenta in rats, but did not demonstrate any teratogenicity or carcinogenicity in rats or rabbits at doses 6–37 times higher than therapeutic human doses.68 An increase in premature delivery and abortion was observed in rabbits at plasma levels 37 times higher than those in humans at therapeutic dose.68 Although telbivudine is a pregnancy category B medication, the safety data for telbivudine in the APR remain limited. Telbivudine has been used in pregnant women with no significant adverse effects in infant [see below].

Although the safety data of telbivudine seems promising, however there is small experience in pregnant women and thus more clinical experience is required in pregnant women.

Entecavir
There is no data regarding placental transfer of entecavir. There were no signs of embryofetal or maternal toxicity when pregnant animals received oral entecavir at approximately 28 (rat) and 212 (rabbit) times the human exposure achieved at the highest recommended human dose of 1 mg/day. In rats, maternal toxicity, embryofetal toxicity (resorptions), lower fetal body weights, tail and vertebral malformations, reduced ossification (vertebrae, sternebrae, and phalanges), and extra lumbar vertebrae and ribs were observed at exposures 3100 times those in humans. In rabbits, embryofetal toxicity (resorptions), reduced ossification (hyoid), and an increased incidence of 13th rib were observed at exposures 883 times those in humans. Entecavir was carcinogenic in both mice and rats. An increase in incidence of lung and other tumors were observed after long-term exposure in rats and mice.69 There are few case reports in the APR on entecavir (44 cases).73 Further cases of entecavir exposure are required to detect an increase in fetal malformations compared with the background rate in the population.

Adefovir Dipivoxil
No increase in tumor incidence has been reported in carcinogenicity studies in mice and rats at 10 and 4 times human doses, respectively. At levels ≥38 times higher than human exposure doses, adefovir given intravenously to pregnant rats was associated with increased fetal malformations like anasarca, depressed eye bulge, umbilical hernia and kinked tail.90 There are few case reports in the APR on adefovir (48 cases).73

Interferons
There have been no clinical studies of interferons in pregnancy; therefore, the safety in this setting has not been established. This, together with its very limited data in animal studies, means that its use is not advised, especially given its known antiproliferative effects.91

PREVENTION OF HEPATITIS B VIRUS TRANSMISSION TO THE NEWBORNS

Prenatal (Antepartum) Stage Interventions

Hepatitis B Immunoglobulin Injection
Although earlier reports showed that antepartum HBIg induced drop in maternal HBV DNA was associated with a modest reduction of mother to infant transmission rates,92–94 recent randomized controlled trial from China showed that antepartum HBIg use was not effective in preventing mother to infant transmission.95 In addition, all newborns from mothers who received antepartum HBIg were negative for anti-HBs at birth in this study, further challenging the hypothesis that HBIg transferred to the fetus would confer passive immunity to the newborn.

Antivirals
Approximately 10% of the offspring of HBV carriers are chronic hepatitis B sufferers in their early life even though they received routine neonatal immunoprophylaxis because they were infected in utero [see above]. The most important determinant of prophylaxis failure has been shown to be maternal serum HBV DNA levels (viral load) [see above].

One strategy for reducing vertical transmission of HBV infection is administering antivirals during pregnancy. Lamivudine was the first drug to be used in such a strategy. A meta-analysis of 10 randomized clinical trials (RCTs) examining 951 HBV carrier mothers was reported to evaluate the efficacy of lamivudine in reducing in utero transmission of HBV.28 The RCTs evaluated included newborns who received immunoprophylaxis at birth and women who were treated with lamivudine from 24 to 32 weeks of gestation, until delivery to 1 month post-delivery. Newborns in the lamivudine group had a 13–24% significantly lower incidence of intrauterine exposure and a lower perinatal infection rate at 9–12 months. This report was limited by the quality of the studies included.28 However, a recent study showed that although the therapy with lamivudine achieved an HBV DNA load reduction of 3 log10 IU/ml, in 20% of the pregnant women, the viral load remained high (>1 × 10^6 IU/ml) and resistant mutations were detectable only after 3 months of therapy,
calling for more potent antiviral drugs to be used to prevent transmission.96

Thus, although most experience is with lamivudine, the use of other nucleos(t)ide analogs may be more desirable for prevention of HBV transmission during pregnancy, given the high resistance rate with use of lamivudine. Each of the oral nucleos(t)ide analogs indicated for the management of HBV infection is listed as either a category B or a category C agent by the US Food and Drug Administration (FDA) (Table 1). Lamivudine, adefovir, and entecavir are designated category C drugs; telbivudine and tenofovir are category B drugs (Table 1).

One recently published study showed the efficacy of telbivudine 600 mg per day in preventing mother to infant transmission when used during the second or third trimesters in highly viremic HBeAg-positive mothers with HBV DNA >6 log10 copies (200,000 IU)/mL.97 The study showed that telbivudine plus vaccination is superior to HBIG and HBV vaccines only in newborns to prevent HBV transmission (0% vs 8%). In this trial, no measurable differences in adverse events or congenital deformities were observed for mothers or newborns when the treatment and control groups were compared up to 28 weeks after birth. This study reconfirms data from a recent study of 31 pregnant women in China, treated with telbivudine started at weeks 28–32 of pregnancy and continued to 30 days postpartum.98 All babies received active and passive immunoprophylaxis. The infection rate was 0% in those treated with telbivudine and 13.3% in the untreated controls.98

Currently, there are no prospective studies published for the use of tenofovir in pregnant women with HBV monoinfection. However, as a pregnancy category B medication, tenofovir has been safely used in pregnant women with HIV (some with HBV co-infection) [see above]. Entecavir and adefovir are not recommended for pregnant women [see above].

**Natal (Intrapartum) Stage Interventions**

**Caesarian Section or Instrument Assisted Delivery**

With regard to mothers to infant transmission of HBV during delivery, disagreements still exist on the issue of whether different mode of delivery (mainly caesarean section versus vaginal delivery) will affect the risk of mother to infant HBV transmission. Of the cases of mothers to infant transmission of HBV, a large proportion occurs during the intrapartum period. Underlying mechanisms may include transfusion of the mother’s blood to the fetus during labor contractions, infection after the rupture of membranes, and direct contact of the fetus with infected secretions or blood from the maternal genital tract. In a recent meta-analysis [four randomized trails involving 789 people were included], there was strong evidence that elective caesarian section (ECS) versus vaginal delivery could effectively reduce the rate of mothers to infant transmission of HBV (ECS: 10.5%; vaginal delivery: 28.0%). The difference between the two groups (elective caesarian section versus vaginal delivery) had statistical significance (Relative risk (RR) 0.41, 95% CI 0.28–0.60, P < 0.001).99 However, methodological concerns including lack of information on randomization procedure, lack of allocation concealment, and lack of blinding, make the role of elective caesarian section for preventing mother to infant transmission of HBV uncertain. More high quality controlled trials are required for assessing the effects of elective caesarian section in comparison to vaginal delivery for preventing mothers to infant transmission of HBV. In addition, elective CS has to be performed before the onset of labor or before the rupture of membranes to achieve effectiveness.99 At this point, most obstetrical algorithms do not include change in the planned mode of delivery for HBsAg-positive women regardless of HBeAg status or level of viremia.99 Current available data did not show any association between the risk of transmission and forceps/vacuum extraction during delivery.100

**Postnatal (Postpartum) Stage Interventions**

**Immunization**

In a recent meta-analysis of clinical trials, the relative risk of neonatal HBV infection in those who received HBV vaccine (plasma-derived or recombinant) was 0.28 [95% confidence interval (CI) 0.2–0.4] compared with those who received placebo or no intervention. Compared with vaccine alone, the addition of HBIG to the regimen further reduced the relative risk (0.54, 95% CI 0.41–0.73) when compared with active prophylaxis only.101 Passive-active immunization with HBV vaccine and HBIG administered 12–24 h after birth, followed by completion of a 3-dose vaccine series, has been demonstrated to be 85%–95% effective in preventing acute and chronic HBV infection in infants born to women who are positive for both HBsAg and HBeAg.102 Although clinical trials have evaluated the efficacy of passive-active immunization with HBV vaccine and HBIG administered only within 24 h of birth, studies of passive immunoprophylaxis have demonstrated that HBIG provided protection when administered as late as 72 h after exposure. Infants born to HBsAg-positive/HBeAg-negative mothers who receive passive-active immunization with HBIG and HBV vaccine are expected to should have the same high degree of protection as infants born to women who are HBsAg positive/HBeAg positive.

Active immunization HBV vaccine alone (i.e., without HBIG) may be used in certain remote areas where implementation of maternal HBsAg testing is difficult because no access exists to a laboratory. In randomized, placebo-controlled clinical trials, administration of hepatitis B vaccine in a 3- or 4-dose schedule without HBIG beginning =12 h after birth has been demonstrated to prevent
70%–95% of perinatal HBV infections among infants born to women who are positive for both HBsAg and HBeAg. Population-based studies in areas with a high endemicity of HBV infection have demonstrated that active immunization is highly effective in preventing infection when the first dose is administered soon after birth, the second at age 1–2 months, and the third at age 6–8 months. All pregnant women should be tested routinely for HBsAg during an early prenatal visit (e.g., first trimester) in each pregnancy, even if they have been previously vaccinated or tested. Women who were not screened prenatally, those who engage in behaviors that put them at high risk for infection (e.g., injection-drug use, having had more than one sex partner in the previous 6 months or an HBsAg-positive sex partner, evaluation or treatment for a sexually transmitted disease, or recent or current injection-drug use) and those with clinical hepatitis should be tested at the time of admission to the hospital for delivery.

**CHRONIC HEPATITIS B VIRUS INFECTION AND BREASTFEEDING**

**Benefits of Breastfeeding**

Breastfeeding in general has short- and long-term benefits both for mothers and children. Breastfeeding, leads to significant reduction in hospitalization rates for gastroenteritis, respiratory infections, and sepsis in the early months of life. In low-resource countries, breastfeeding has been related to better infant and childhood survival. For older children, role of prolonged breastfeeding in development of cognitive functions has been proposed. For older children and adults, a possible impact of breastfeeding on cholesterol levels, body mass index, obesity and type 2 diabetes. The benefits of breastfeeding for mothers are well known. Oxytocin-stimulated uterus contraction prevents anemia. Lactation-induced suppression of ovulation has contraceptive effect during the period of exclusive breastfeeding. Lactating women seem to regain their pre-pregnant weight sooner, and in the long-term have reduced obesity risk. The risks of breast and ovarian cancer and osteoporosis are also decreased. Besides all these, breastfeeding enhances emotional bonding and close mother to infant contact.

**Chronic Hepatitis B Virus Infected Mother and Safety of Breastfeeding**

HBsAg, HBeAg and HBV DNA have been detected in breast milk. Also both colostral HBsAg and HBeAg titers correlate positively with the corresponding levels in the maternal blood. In Chinese studies, HBV DNA has been detected in 76.9–81.25% breast milk of mothers if mothers were HBsAg and HBeAg were positive and in 5.75–45.24% if HBeAg was negative. In a recent meta-analysis based on 32 studies, it was found that the difference in risk of the infection between breastfed and formula-fed infants born to chronic HBV-infected mothers was −0.8% (95% confidence interval [CI]: −1.6%, 0.1%). Furthermore, analysis of the data from 16 of the studies found that difference in risk of the infection between breastfed and formula-fed infants for mothers who are positive for the HBeAg and/or the HBV DNA, was similar to that for those who are negative for these infectivity markers [0.7% (95% CI: −2.0%, 3.5%) vs −0.5% (95%CI: −1.7%, 0.6%), P = ns]. Thus, although breast milk is infectious; yet, breastfeeding, even by mothers with high infectivity, is not associated with demonstrable risk of infantile chronic HBV infection, provided that the infants have been vaccinated against HBV at birth. Even in cases of no active or passive prophylaxis, the risk of transmission from HBV-positive mothers to their breastfed infants is the same. Bacteriostatic, bactericidal and antiviral activities of lactoferrin are well known. Recent studies have also shown anti-HBV effects of lactoferrin.

**Antivirals and Breastfeeding**

The period immediately after birth is a time of treatment uncertainty in mothers who choose to breastfeed, because nucleoside analogs are likely to pass into the breast milk to some degree, and it is probably unwise to expose the child in this manner. Lamivudine is found in higher concentrations in human breast milk than serum. However, given the actual concentration, coupled with the average volume of feed ingested by an infant, suggest that amount of drug the infant would be exposed to via this route is negligible compared to standard oral dosing. In one recent study, the median breast milk concentration of lamivudine in 67 HIV-infected women treated with a combination of lamivudine, zidovudine and nevirapine was 1214 ng/ml.
compared to 508 ng/ml in maternal plasma (breast milk to plasma ratio 2.56).133

**Tenofovir**

Tenofovir is present at low concentrations in human breast milk.134 But its oral bioavailability is limited and thus infants are exposed to only small concentrations.134

**Telbivudine**

Data on human placental passage and breast milk excretion are not available.

**Entecavir**

Entecavir monohydrate or its conjugate metabolites are excreted in milk of rats, but it is not known whether human breast milk excretion occurs.

**Adefovir**

It is not known whether adefovir is excreted in human or animal milk.

European Association for the Study of the Liver (EASL) 2012 guidelines recommend that HBsAg can be detected in breast milk, but breastfeeding may not be considered a contraindication in HBsAg-positive mothers. The safety of nucleos(t)ide analog (NA) therapy during lactation is uncertain.135

**MANAGEMENT OF CHBV INFECTION IN WOMEN WHO DESIRE PREGNANCY**

EASL 2012 guidelines recommends that family planning should be always discussed with women of childbearing age before initiating HBV therapy. The woman should be informed about the safety data of the drugs on a possible pregnancy (A1). In a woman of childbearing age without advanced fibrosis who plans a pregnancy in the near future, it may be prudent to delay therapy until the child is born (C1). In a woman of childbearing age with advanced fibrosis or cirrhosis who agrees for a “planned pregnancy” in the future, pegylated interferon (PEG-IFN) therapy may be tried as it is given for a short period of time (C1). It should be noted that effective contraception is required during PEG-IFN therapy. If PEG-IFN is not possible or has failed, treatment with a nucleos(t)ide analog (NA) has to be initiated and maintained even during a future pregnancy (C1). Telbivudine is preferred because of its high potency, high genetic barrier and available safety data in pregnancy (C1).135 The Asian Pacific Association for the Study of the Liver (APASL) 2012 guidelines recommends that for female patients of childbearing age, IFN-based therapy is preferred for nonpregnant women. Pregnancy is discouraged during IFN therapy (IA). Pregnant women who need treatment can be treated with category B nucleos(t)ide analog (NA) (IIA).136 Figure 1 shows the approach to women with chronic HBV infection who desire pregnancy.

**MANAGEMENT OF CHBV INFECTION IN WOMEN WHO BECOME PREGNANT WHILE TAKING ANTIVIRALS OR ARE FIRST DETECTED DURING PREGNANCY**

If a pregnancy occurs in a woman already receiving a medication for HBV, decisions must be individualized. When a woman on HBV antiviral therapy becomes pregnant, decision has to be taken whether to continue therapy in pregnancy or withdraw therapy immediately. In this regard, health of the mother and the fetus must be considered independently. Fetal concerns are regarding the risk of exposure to medication during early embryogenesis. From fetal point of view, withdrawal during pregnancy is preferable, especially to the mother who wants to avoid any potential future risk to the fetus. Maternal concerns include whether stopping or changing medication will adversely affect both short- and long-term liver disease outcomes. First decision to be made is if the antiviral treatment can be stopped completely. Data specifically addressing the risk of stopping therapy during pregnancy are not available. In early antiviral studies in nonpregnant, therapy was stopped after completion of the trial, even for patients who remained HBeAg-positive. In general, if mild fibrosis is there, HBV DNA levels rebound, but clinically significant flares of hepatitis have been rare; but in cases of advanced fibrosis or cirrhosis, flares upon treatment withdrawal can result in decompensation.137-139 Overall, it appears the risk of an adverse outcome with continuing antiviral therapy during pregnancy is likely very low. However, therapy could be discontinued with close observation of the mother to avoid continued fetal exposure during the first trimester, especially in the patient who does not have advanced fibrosis (Figure 2).

EASL 2012 guidelines recommend that, if female patients become pregnant during anti-HBV therapy, treatment indications should be reevaluated (C1). Patients with advanced fibrosis or cirrhosis should definitely continue to be treated, but the treating agent should be reconsidered (C1). PEG-IFN must be stopped and the patients should continue on a NA, while FDA category C NAs, particularly adefovir and entecavir, should be changed to a FDA category B NA (C1). Among FDA category B NAs, tenofovir is preferred because of its high potency, high genetic barrier and available safety data in pregnancy (C1).135 The same treatment indications apply to women who are first diagnosed to have chronic HBV infection during pregnancy (Figure 3), with patients with advanced fibrosis or cirrhosis should be started on treatment with appropriate NAs.135

All patients should have HBV DNA levels repeated in last trimester. The prevention of mother to infant transmission, which is considered to occur mainly at delivery, is traditionally based on the combination of passive and active immunization with hepatitis B immunoglobulin.
(HBsAg) and HBV vaccination. Such a strategy, however, may not be effective in a proportion of newborns from highly viremic (serum HBV DNA > 10^6–7 IU/mL). Mothers with these high concentrations of HBV DNA should be informed that utilizing a NA to reduce their viral loads could add to the effectiveness of HBsAg and vaccination (B1). Lamivudine and recently telbivudine therapy during the last trimester of pregnancy in pregnant HBsAg-positive women with high levels of viremia have been shown to be safe and to reduce the risk of intrauterine and perinatal transmission of HBV if given in addition to passive and active vaccination by HBsAg and HBV vaccination (B1). Thus, telbivudine, lamivudine or tenofovir (as a potent FDA category B agent) may be used for the prevention of perinatal and intrauterine HBV transmission in the last trimester of pregnancy in HBsAg-positive women with high levels of viremia (serum HBV DNA >10^6 IU/mL) (B1). No controlled clinical trial of tenofovir to prevent perinatal transmission has been conducted. If NA therapy is given only for the prevention of perinatal transmission, it may be discontinued within the first 3 months after delivery (C1). APASL 2012 guideline recommends that for the prevention of mother to infant transmission, pregnant women with high HBV DNA (>2 × 10^6 IU/mL) can be treated with telbivudine in the third trimester (IIA). Tenofovir is an alternative (IIIA). Although different maternal HBV DNA thresholds have been suggested for antiviral use in last trimester, the recent Chinese study found that HBV immunoprophylaxis failure occurred among infants born to HBeAg-positive mothers with HBV DNA levels >6 log10 copies/mL and no immunoprophylaxis failure occurred in infants born to the mothers who were HBeAg negative or had HBV DNA levels <6 log10 copies/mL. This study also found that 81 percent of the infants with immunoprophylaxis failure were born to the mothers with DNA levels between 6 and 7 log10 copies/mL. In view of these findings, it seems reasonable to use 6 log10 copies/mL as the threshold for maternal antiviral treatment during last trimester with the aim to interrupt mother to infant transmission.

EASL 2012 guidelines recommend that if a pregnant woman remains untreated or anti-HBV therapy is discontinued during pregnancy or early after delivery for any reason, close monitoring of the patient is necessary, as there is a risk of hepatic flares, especially after delivery (B1).

SUMMARY

Chronic HBV infection is usually mild in pregnant women, but may flare shortly after delivery. Effect of HBV infection on pregnancy outcomes is generally favorable, but may depend on severity of liver disease. All decisions about initiating, continuing, or stopping therapy of the chronic hepatitis B virus infection during pregnancy must include an analysis of the risks and benefits for mother and fetus. Mother to infant transmission can be minimized by current immunoprophylaxis strategies, however high levels of viremia in mothers may be a factor in the failure of current immunoprophylaxis strategies. Antiviral therapy during late stages of pregnancy is the most effective method to reduce transmission from mothers with high levels of viremia. Use of antivirals during pregnancy needs to be individualized. Breastfeeding, is generally not recommended while receiving antiviral therapy.

CONFLICTS OF INTEREST

All authors have none to declare.

REFERENCES

PREGNANCY AND CHRONIC HEPATITIS B


47. Chu CJ, Hussain M, Lok ASF. Hepatitis B virus genotype B is associated with earlier HBeAg serocconversion compared with hepatitis B virus genotype C. Gastroenterology. 2002;122:1756–1762.


96. Ayres A, Yuen L, Manoharan S, et al. Lamivudine in Late Preg-
nancy for Prevention of HBV Transmission: Effectiveness and De-
tection of Antiviral Resistance. J Hepatology. 2011;54(suppl 1):
S295–S296.
97. Han G-R, Cao MK, Zhao W, et al. A prospective open-label study
for the efficacy and safety of tselbivudine in pregnancy for the pre-
vention of perinatal transmission of hepatitis B virus to the infant.
98. Zhang LJ, Wang L. Blocking intrauterine infection by tselbivudine in
pregnant chronic hepatitis B patients. Zhonghua Gan Zang Bing
99. Yang J, Zeng XM, Men YL, Zhao LS. Elective caesarean section ver-
sus vaginal delivery for preventing mother to child transmission of
100. Wang J, Zhu Q, Zhang X. Effect of delivery mode on maternal infant
transmission of hepatitis B virus by immunoprophylaxis. Chin Med
101. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B im-
munization in newborn infants of mothers positive for hepatitis B
surface antigen: systematic review and meta-analysis. BMJ.
2006;332:328–336.
102. Andre FE, Zuckerman AJ. Review: protective efficacy of hepatitis B
103. Milne A, West DJ, Chinh DV, Moyses CD, Poerschke G. Field eval-
uation of the efficacy and immunogenicity of recombinant hepati-
sis B vaccine without HBIG in newborn Vietnamese infants. J Med
104. Assateerawatt A, Tanphaichitr VS, Suvatte V, In-Ngarm L. Immu-
nogenicity and protective efficacy of low dose recombinant DNA
hepatitis B vaccine in normal and high-risk neonates. Asian Pac
105. Hsu HM, Chen DS, Chuang CH, et al. Ef-
fectiveness and immunogenicity of recombinant hepati-
sis B vaccine without HBIG in newborn infants. J Med
chronic hepatitis B virus infections: results of the Alaska immuni-
107. Mast EE, Margolis HS, Fiore AE, et al. Advisory Committee on Immu-
nization Practices (ACP). A comprehensive immunization strategy
to eliminate transmission of hepatitis B virus infection in the United
States: recommendations of the Advisory Committee on Immuniza-
tion Practices (ACIP) part 1: immunization of infants, children,
108. Quigley MA, Kelly YJ, Sacker A. Breastfeeding and hospitalization
for diarrheal and respiratory infection in the United Kingdom Mil-
109. Effect of breastfeeding on infant and child mortality due to infec-
tious diseases in less developed countries: a pooled analysis.
WHO Collaborative Study Team on the Role of Breastfeeding on
110. Jones G, Steketee RW, Black RE, Bhutta ZA, Morris SS. How many
child deaths can we prevent this year? Lancet. 2003;362:85–71.
cognitive development: new evidence from a large randomized
ing effects on the IQ by genetic variation in fatty acid metabolism.
choices modulate later obesity risk? Am J Clin Nutr. 2009;89:
1502S–1508S.
choices modulate later obesity risk? Am J Clin Nutr. 2009;89:
1502S–1508S.
lead to lower blood cholesterol in adult life? A quantitative review
116. Petrova M, Kamburov V. Breastfeeding and chronic HBV infection:
clinical and social implications. World J Gastroenterol.
2010;16(40):5042–5046.
117. Breast cancer and breastfeeding: collaborative reanalysis of indi-
vidual data from 47 epidemiological studies in 30 countries, in-
cluding 50302 women with breast cancer and 96973 women
118. Shantakumar S, Terry MB, Teitelbaum SL, et al. Reproductive fac-
tors and breast cancer risk among older women. Breast Cancer
119. Gwinn ML, Lee NC, Rhodes PH, Layde PM, Rubin GL. Pregnancy,
breast feeding, and oral contraceptives and the risk of epithelial
1974;2:155.
121. Ma L, Zhao GZ, Liang ZL. Relationship between load of HBV-DNA
in serum and breast milk for pregnant women and safety of breast-
122. Lin HH, Hsu HY, Chang MH, Chen PJ, Chen DS. Hepatitis B virus in
the colostrum of HBeAg-positive carrier mothers. J Pediatr Gastroen-
123. Yang D, Li Y, Song J. Significance of detection of HBV-DNA and
CMV-DNA by polymerase chain reaction in screening mothers' milk.
Hunan Yi Ke Da Xue Xue Bao. 1999;24(1):44–46 [Article in
Chinese].
124. He JY, Zhang YH, Zhang YL, Huang HF. Instructional signification
of HBV-DNA load in maternal milk on breastfeeding of postpartum
women infected with HBV. Zhonghua Ju Fang Yi Xue Za Zhi.
126. Li S, Zhou H, Huang G, Liu N. Inhibition of HBV infection by bovine
lactoferrin and iron-, zinc-saturated lactoferrin. Med Microbiol Im-
rus infection in cultured human hepatocytes. Hepatol Res.
2002;24(3):228.
128. Sembra RD, Kumwenda N, Hoover DR, et al. Human immunodefi-
ciency virus load in breast milk, mastitis, and mother-to-child
transmission of human immunodeficiency virus type 1. J Infect
Dis. 1999;180:93–98.
milk HIV-1 viral load, blood prolactin levels and breast milk vol-
ume. AIDS. 2006;20:1539–1547.
130. Tran TT. Management of hepatitis B in pregnancy: weighing the
131. Shapiro RL, Holland DT, Capparelli E, et al. Antiretroviral con-
tractions in breast-feeding infants of women in Botswana receiving
132. Moodley J, Moodley D, Pillay K, et al. Pharmacokinetics and anti-
retroviral activity of lamivudine alone or when coadministered
with zidovudine in human immunodeficiency virus type 1-infec-
ted pregnant women and their offspring. J Infect Dis.
133. Mirochnick M, Thomas T, Capparelli E, et al. Antiretroviral con-
tractions in breast-feeding infants of mothers receiving highly ac-
134. Benaboud S, Pruvost A, Coffie PA, et al. Breast milk concentra-
tions of tenofovir and emtricitabine in HIV-1 infected women
in Abidjan TEmAA Step 2 (ANRS 12109). Antimicrob Agents